Log In
BCIQ
Print this Print this
 

Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50)

  Manage Alerts
Collapse Summary Pipeline Information
 Pipeline Summary for Products Targeting Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50)

BCIQ
Print ChartPrint this
1 - Autoimmune 1 - Inflammation 2 - Endocrine / Metabolic 2 - Dermatology 1 - Cancer 1 - Autoimmune 1 - Musculoskeletal 1 - Cancer 1 - Autoimmune 1 - Renal 1 - Neurology 1 - Musculoskeletal 2 - Inflammation 1 - Hematology 1 - Endocrine / Metabolic 1 - Cardiovascular 4 - Cancer 1 - Autoimmune 1 - Cancer 1 - Renal 1 - Pulmonary 3 - Neurology 1 - Musculoskeletal 1 - Cancer 1 - Autoimmune 2 - Inflammation
Phase of DevelopmentDiscoveryPreclinicalINDPhase IPhase I/IIPhase IIMarketed
Autoimmune

-

1

-

1

1

1

1

Cancer

-

1

1

4

1

1

-

Cardiovascular

-

-

-

1

-

-

-

Dermatology

-

-

-

-

-

2

-

Endocrine / Metabolic

-

-

-

1

-

2

-

Hematology

-

-

-

1

-

-

-

Inflammation

2

-

-

2

-

1

-

Musculoskeletal

-

1

-

1

1

-

-

Neurology

-

3

-

1

-

-

-

Pulmonary

-

1

-

-

-

-

-

Renal

-

1

-

1

-

-

-




 Products Targeting Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50)
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Summary
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

6

$287.0M

$35.0M

$237.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury Trial today